.png){kind=icon}
Return
COMPLEMENTing immunotherapy
.png){kind=icon}
PRE
AI
DOI：10.1038/s43018-022-00442-6.png)
.png){kind=icon}
.png){kind=icon}
Share.png){kind=icon}
Save
Abstract
En 中文
Intratumoral activation of the complement cascade may have therapeutic potential in patients with lung cancer with strong EGFR signaling, shows a new study. EGFR-triggered expression of CD55 and CD59 prevents opsonization of tumor cells, inhibits antitumor immunity and confers resistance to immune-checkpoint inhibitors.
Keywords:
LUNG-CANCER
ACTIVATION
BLOCKADE
Journal
IF:
28.5
Papers:
1.3K
Citations:
1.3W
Organization
Cited Papers
ShareSaveTertiary lymphoid structures generate and propagate anti-tumor antibody-producing cells in renal cell cancer.png)
IMMUNITY
OAAI
IMMUNITYIF26.3
OAAIShareSaveComplement Activation via a C3a Receptor Pathway Alters CD4+ T Lymphocytes and Mediates Lung Cancer ProgressionCANCER RESEARCHOAAI
CANCER RESEARCHIF16.6
OAAIShareSaveShareSaveSilencing EGFR-upregulated expression of CD55 and CD59 activates the complement system and sensitizes lung cancer to checkpoint blockadeNATURE CANCER
NATURE CANCERIF28.5
PREAI
ShareSaveComplement activation mediates cetuximab inhibition of non-small cell lung cancer tumor growth in vivoMOLECULAR CANCEROAAI
MOLECULAR CANCERIF33.9
OAAIShareSaveShareSaveA Combined PD-1/C5a Blockade Synergistically Protects against Lung Cancer Growth and MetastasisCANCER DISCOVERYOAAI
CANCER DISCOVERYIF33.3
OAAIShareSave
View more